Golimumab in Treatment-Refractory Hidradenitis Suppurativa

This cohort study examines the association of a change in International Hidradenitis Suppurativa Severity Score System score with intravenously and subcutaneously administered golimumab in patients with moderate to severe hidradenitis suppurativa.

Corresponding Author: Madeline Sage, BS, Department of Dermatology, University of North Carolina School of Medicine, Chapel Hill, NC 27516 (madeline_sage@med.unc.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.